Pombiliti +
BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion
BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases
Actionable Insights Powered by AI
BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases